Associated Papers
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA et al.
Endocrine Reviews, 2023
Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
Choi WW et al.
Current Oncology Reports, 2023
Structural basis for the allosteric inhibition of hypoxia-inducible factor (HIF)-2 by belzutifan.
Ren X et al.
Molecular Pharmacology, 2022
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Hasanov E et al.
Expert Opinion on Investigational Drugs, 2021
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
Wehn PM et al.
Journal of Medicinal Chemistry, 2018
Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers.
Wei J et al.
Cancers, 2018
Select a paper to view details